*Members are listed in alphabetical order by last name
Investor, Stanford Angels & Entrepreneurs
Charles Cheng is a venture capital investor. He is a member of Stanford Angels & Entrepreneurs, an advising expert at Alumni Ventures Group, and former Risk Management Partner & China Chief Investment Officer at Amino Capital. He obtained his LLM from Stanford Law School, his Ph.D. in Jurisprudence from Wuhan University, and a graduate certificate in international relations from the Johns Hopkins School of Advanced International Studies’ Nanjing Center.
Director, Head of Suzhou Analytical Research and Development, BeiGene, China
Yang has been with the pharmaceutical industry for almost a decade with research and management experience at bioanalytical and small molecule CMC. Prior to BeiGene, Yang worked at Gilead Sciences and Covance, with a focus on analytical sciences and control strategy development. Yang graduated from Purdue University with a Ph.D. in analytical chemistry and Peking University with a B.S. in Pharmaceutical Sciences.
Software Engineer, Google Health
Growing up in a beautiful small city in China, Yangzhou, I came to the U.S. after obtaining my bachelor's degree in Software Engineering at Nanjing University, China. I had my master's degree in Computer Science at UC Santa Barbara, where my research area was modeling biochemical systems with cloud computing (www.stochss.org). I'm now working on a clinician tool at Google Health. Outside work, I really enjoy running, hiking, playing table tennis and traveling. I adopted my dog rescued from Taiwan 3 years ago, and have been really interested in dog rescuing and training since then.
Attorney, Goodwin Procter, LLP
Qing Han is the co-founder of LEAP. He is currently an attorney in Silicon Valley, whose practice focuses on cross-border and domestic corporate transactions in the life science industry. Prior to that, he worked for five years as a diplomat, in the Chinese Ministry of Foreign Affairs in Beijing, and the Permanent Mission of China to the UN in New York. Qing got his J.D. from Harvard Law School in 2018, and his B.A. from Nanjing University in 2009.
Founder & CEO of Twenty Five, Inc.
Wenbing has previously launched two fintech startups and currently working on Twenty Five, a new consumer brand offering healthy and affordable food. Before founding Twenty Five, he found Echo Microfinance, which provided financial services like lending and savings to the urban slum dwellers in Mexico and Argentina. He also built Hustlebeez, a mobile personal finance manager, offered a personalized debt & payment manager to the millennials. During undergrad, Wenbing studied physics and computer science at Stanford University. And studied Finance at UTampa.
Director of Investment, Wuixi AppTec Investment Department, China
Medical BD head in Oncology at AstraZeneca(China), Medical Affairs-Oncology (2020~); BD at CSPC (2019~2020); Former President of UCSF-ACSS (2017~2018); Post-doctoral Fellow at UCSF (2016~2019). Dr. Li has more than 10 years of experience in drug development. Academically, Dr. Li has published 30 professional articles in SCI journals and authorized 2 patents and was invited to be a professional reviewer for 8 internationally renowned journals. After joining CSPC and AZ, Dr. Li led the evaluation of more than 60 top-tier biotech companies, including more than 150 innovative drug projects, and promoted multiple innovative drug projects to the company's board.
Hardware Research Engineer, Twenty/Twenty Therapeutics
Dr. Zidong Li is a Hardware Research Engineer at Twenty/Twenty Therapeutics, a joint venture between Google and Santen Pharmaceuticals. Previously, he worked at Google Life Sciences (Verily) and Google AI Research, working on biosensors and next-generation smart medical devices. He holds a Ph.D. in Biomedical Engineering, an M.S in Mechanical Engineering, and a B.S in Energy Power Engineering. In his spare time, he enjoys hiking and all kinds of sports.
Associate Director, Kriya Therapeutics
Weiran Shen is the Associate Director of Vector Design and Innovation at Kriya Therapeutics. Before joining Kriya, Weiran was a lead scientist at Sangamo Therapeutics, where he led the efforts to design novel AAV vectors to treat CNS diseases. Prior to Sangamo, Weiran led a group at the discovery lab in the Gene Therapy Program at the University of Pennsylvania. His role was to develop the production system of a novel vector, improve vector production, and rationally design gene therapy vectors. Weiran held a Ph.D. degree in Virology and an M.S. degree in Neuroscience.
Founding Partner, Yuhang Capital, Yuhang Asset Management Co., Ltd
Baylor obtained a master's degree in financial mathematics from Stanford University. In 2017, Baylor founded Yuhang Capital in the US and established a fund of $200 million which has subsequently invested in the IPO of Xiaomi INC and China Tower. Baylor leads and invests in the development of the CITRIS-Zhejiang Partnership and helps to introduce CITRIS (University of California) into Xiaoshan District. Baylor was invited to speak at the Davos Forum of Young Global Leaders in 2017 and was also awarded the Top 100 young leaders in the US.
Anthony Boshen Wu
Sr. Director at Brii BioSciences, COO at TSB Therapeutics, China
Anthony Boshen Wu currently works as COO at TSB Therapeutics (a subsidiary of Brii BioSciences), a company that makes effective antibodies to fight COVID-19. He received medical training at Peking University and pursued a Ph.D. at the University of Oxford. He has a broad spectrum of working experience at management consultancy, investment, pharma, and biotech startup.
Xiaoyu Janice Zang
Founder, CEO & President, N1 Life, Inc.
Janice is a scientist entrepreneur with a Ph.D. in chemistry from Stanford. The objective of her research has focused on delivering diagnostic and therapeutic agents to diseased tissues and cells across biological barriers. She founded N1 Life to develop innovative therapeutics for resistant diseases. Having served in several organizations, she is also a passionate contributor to life science and entrepreneurship communities in Silicon Valley.
Assistant Professor, Peking University
Co-founder of the LEAP initiative. Liqin has been passionate about entrepreneurship in healthcare and other related fields. Prior to the current professorship position at Peking University School of Pharmaceutical Sciences, he worked at Thermo Fisher Scientific and several startup programs in Silicon Valley. He was also a postdoctoral researcher at Stanford University Medical School. Liqin got his B.S. and M.S. in pharmaceutical sciences at Peking University and a Ph.D. in biochemistry from the University of Florida.